Skip to content

US · APLMW · BIOTECHNOLOGY

Apollomics, Inc. (APLMW) intrinsic value and stock valuation

$0.01as of 2026-11-21 · Mkt cap 235M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Apollomics, Inc. DCF and intrinsic value

InvestorsCraft values APLMW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from APLMW’s statements →

Apollomics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Foster City, CA 94404 apollomicsinc.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$8.5M+35.8% 5y CAGRd
20192025
Net income
-$-10.94M
20192025
Free cash flow
-$-10.37M
20192025
Total equity
-$-3.19M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$8.5M$200K$820K$320K$0.00
Operating income-$-9.47M-$-42.14M-$-54.01M-$-45.08M-$-50.86M
Net income-$-10.94M-$-53.86M-$-172.6M-$-240.81M-$-94.8M
EPSd-$-7.54M-$-57.91M-$-233.24M-$-276.79M-$-108.97M
Operating cash flow-$-10.37M-$-28.74M-$-43.21M-$-42.82M-$-43.31M
Capital expenditure$0.00-$-20K-$-10K-$-370K-$-50K
Free cash flow-$-10.37M-$-28.77M-$-43.22M-$-43.19M-$-43.36M
Total assets$6.71M$13.1M$55.4M$76.5M$123.4M
Total debt$640K$970K$4.66M$990K$325.4M
Net debt-$-2.63M-$-8.8M-$-27.39M-$-31.68M$278.7M
Total equity-$-3.19M$4.86M$41.2M-$-448.12M-$-212.86M
Cash and short-term investments$3.28M$9.77M$37.8M$54.6M$94.5M
Income statement
20252024202320222021
Revenue$8.5M$200K$820K$320K$0.00
Cost of revenue$260K$0.00$0.00$0.00$0.00
Gross profit$8.24M$200K$820K$320K$0.00
Research and development expenses$5.53M$24.6M$34.2M$35.5M$35.6M
Selling, general and administrative expenses$12.4M$17.8M$20.6M$9.95M$15.3M
Other expenses-$-260K$0.00$0.00$0.00$0.00
Operating expenses$17.7M$42.3M$54.8M$45.4M$50.9M
Cost and expenses$18M$42.3M$54.8M$45.4M$50.9M
Interest income$150K$480K$750K$430K$470K
Interest expense$70K$180K$150K$90K$80K
Depreciation and amortization$260K$70K$100K$180K$150K
Ebitda-$-9.22M-$-41.05M-$-53.45M-$-43.88M-$-50.12M
Operating income-$-9.47M-$-42.14M-$-54.01M-$-45.08M-$-50.86M
Total other income/expenses, net-$-1.46M-$-11.46M-$-118.58M-$-195.73M-$-43.94M
Income before tax-$-10.94M-$-53.6M-$-172.59M-$-240.81M-$-94.8M
Income tax expense$0.00$260K$10K$0.00$0.00
Net income-$-10.94M-$-53.86M-$-172.6M-$-240.81M-$-94.8M
Weighted average shares outstanding$1.45M$930K$740K$870K$870K
Weighted average diluted shares outstanding$1.45M$930K$740K$870K$870K
Balance sheet
20252024202320222021
Cash and short-term investments$3.28M$9.77M$37.8M$54.6M$94.5M
Net receivables$2.49M$130K$470K$550K$510K
Inventory$0.00$0.00$0.00$0.00$2.25M
Total current assets$6.05M$10.3M$39.9M$55.8M$99.4M
Property, plant and equipment, net$580K$1.02M$590K$1.48M$1.32M
Goodwill and intangible assets$0.00$1.74M$14.8M$14.8M$14.8M
Long-term investments$0.00$0.00$0.00$4.31M$7.84M
Total non-current assets$660K$2.83M$15.5M$20.7M$24.1M
Total assets$6.71M$13.1M$55.4M$76.5M$123.4M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$210K$230K$4.39M$610K$2.66M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$6.33M$7.4M$13.6M$12.4M$13.6M
Long-term debt$430K$730K$270K$380K$322.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$3.62M
Total non-current liabilities$3.58M$830K$600K$512.2M$322.7M
Capital lease obligations$640K$970K$420K$990K$1.04M
Total liabilities$9.9M$8.23M$14.2M$524.6M$336.3M
Common stock$20K$10K$10K$40K$40K
Retained earnings-$-711.76M-$-700.82M-$-646.97M-$-474.6M-$-235.44M
Accumulated other comprehensive income (loss)$3.44M$3.44M$26.7M$3.4M$12.3M
Total equity-$-3.19M$4.86M$41.2M-$-448.12M-$-212.86M
Total investments$0.00$0.00$5.76M$26.3M$55.6M
Total debt$640K$970K$4.66M$990K$325.4M
Net debt-$-2.63M-$-8.8M-$-27.39M-$-31.68M$278.7M
Cash flow statement
20252024202320222021
Net income-$-10.94M-$-53.86M-$-172.6M-$-240.81M-$-94.8M
Depreciation and amortization$260K$360K$670K$780K$680K
Stock-based compensation-$-980K$10.9M$12.7M$3.58M$8.12M
Change in working capital-$-380K$1.61M-$-930K$3.65M-$-450K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-10.37M-$-28.74M-$-43.21M-$-42.82M-$-43.31M
Investments in property, plant and equipment$0.00-$-20K-$-10K-$-370K-$-50K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$220K$5.98M$21.4M$29.1M-$-38.95M
Common stock issued$10K$5.05M$17.6M$390K-$-1.03M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$3.68M$470K$21.2M-$-290K-$-1.64M
Net change in cash-$-6.49M-$-22.29M-$-620K-$-14.06M-$-83.91M
Cash at end of period$3.28M$9.77M$32.1M$32.7M$46.7M
Operating cash flow-$-10.37M-$-28.74M-$-43.21M-$-42.82M-$-43.31M
Capital expenditure$0.00-$-20K-$-10K-$-370K-$-50K
Free cash flow-$-10.37M-$-28.77M-$-43.22M-$-43.19M-$-43.36M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Apollomics, Inc.

        Apollomics, Inc. functions as a clinical-phase biotechnology enterprise, concentrating its efforts on discovering and advancing novel cancer treatments to meet crucial, underserved patient requirements. The company was co-founded by Liang Yu Guo and Sanjeev Redkar in 2015, with its main operations based in Foster City, California.

        CEO
        Hung-Wen Chen
        Employees
        14
        Beta
        2.05

        Explore

        Frequently asked questions

        What is the intrinsic value of Apollomics, Inc. (APLMW)?

        InvestorsCraft does not currently publish an intrinsic value for APLMW. How the IC value is calculated.

        Is APLMW undervalued?

        InvestorsCraft does not publish an undervaluation signal for APLMW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.